TAS102 in Combination With NAL-IRI in Advanced GI Cancers
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Active, not recruiting · NCT03368963 · Registry updated 2025-01-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal adenocarcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, gastric adenocarcinoma, gastric neoplasm, intestinal disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, stomach disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-01-07 | NCT03368963 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Emory University | 393 |
| Ipsen | 59 |
| Taiho Oncology, Inc. | 24 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory Saint Joseph's Hospital | Atlanta | United States | 175 |
| Emory University Hospital Midtown | Atlanta | United States | 246 |
| Emory University Hospital/Winship Cancer Institute | Atlanta | United States | 299 |